Dr Mark Evans is a University Lecturer at the University of Cambridge and an Honorary Consultant Physician at the Cambridge University Hospitals NHS Foundation Trust. He is many research interests such as how the brain detects changes in blood glucose and how this glucose-sensing interacts with peripheral metabolism. Also how defences against hypoglycaemia (low blood sugar) may become abnormal in diabetes; the short and long term effects of episodes of hypoglycaemia on brain and new and innovative technology for monitoring and managing diabetes. This includes the development of closed loop insulin pump systems (the “artificial pancreas”). Mark leads now leads the CamT1D team.
Camt1D was originally set up 5 years ago by Dr Frank Waldron-Lynch who is a consultant endocrinologist and specialist in type 1 diabetes. He is also a scientist researching the immune system, type 1 diabetes (T1D) and other autoimmune diseases. Whilst Frank is no longer resident in Cambridge he remains and influential and key member of the team collaborating on many studies. Under Franks direction the team completed two innovative clinical research studies (“DILT1D”, “DILfrequency”) looking at low dose Interleukin-2 as a potential new therapy for Type 1.
The department of Clinical Biochemistry forms part of the Department of medicine at the University of Cambridge and is part of the Metabolic Research Laboratories (MRL). The Institute of Metabolic Science houses the MRL and is firmly embedded within the fast developing Biomedical Research Campus in the heart of Cambridge. This world class centre of excellence offers unrivalled access to cutting edge clinical research facilities and allows for successful collaboration with the Cambridge University Hospitals NHS Foundation Trust as well as the other pharmaceutical and biotech companies on site.
The team is highly active in the field of early phase clinical research studies (both academic and commercial) investigating potential new therapies. Other research trying to understand more about the disease process, how it occurs and what we can do to prevent its onset is always ongoing here in Cambridge.
Watch Dr Frank Waldron-Lynch and research nurse Jane Kennet talk about our trials into potential new immunotherapy treatments in the following video.
For more videos about the CamT1D sample process and benefits of participation visit our YouTube page.